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Alzheimer’s disease (AD) is an age-related neurolog-
ical disorder characterized by synaptic loss and de-
mentia. The low-density lipoprotein receptor-related
protein 6 (LRP6) is an essential coreceptor for Wnt
signaling, and its genetic variants have been linked
to AD risk. Here we report that neuronal LRP6-medi-
atedWnt signaling is critical for synaptic function and
cognition. Conditional deletion of Lrp6 gene in
mouse forebrain neurons leads to age-dependent
deficits in synaptic integrity and memory. Neuronal
LRP6 deficiency in an amyloid mouse model also
leads to exacerbated amyloid pathology due to
increased APP processing to amyloid-b. In humans,
LRP6 and Wnt signaling are significantly downre-
gulated in AD brains, likely by a mechanism that
depends on amyloid-b. Our results define a critical
pathway in which decreased LRP6-mediated Wnt
signaling, synaptic dysfunction, and elevated Ab
synergistically accelerate AD progression and sug-
gest that restoring LRP6-mediated Wnt signaling
can be explored as a viable strategy for AD therapy.
INTRODUCTION
The low-density lipoprotein receptor-related protein 6 (LRP6) is
an essential coreceptor for the canonical Wnt pathway. Wnt li-
gands activate the pathway by binding to LRP6 cooperatively
with Frizzled receptors and transduce signal through the stabili-
zation of b-catenin. The stabilized b-catenin in turn translocates
to the nucleus, where it activates Wnt target genes (Niehrs,
2012). Wnt signaling, which regulates diverse developmental
processes in the nervous system (Budnik and Salinas, 2011),
has been implicated in themodulation of neurogenesis, dendriticmorphogenesis, and synaptic function (Inestrosa and Arenas,
2010; Park and Shen, 2012). Synapses and dendritic spines
are dynamic structures whose plasticity underlies learning and
memory (Bourne and Harris, 2008). Wnt ligands have also been
shown to modulate neurotransmitter release at the presynaptic
terminal (Cerpa et al., 2008). In the postsynaptic regions, Wnt
signaling regulates the trafficking of glutamate receptors and
their interactions with postsynaptic density protein 95 (PSD-95)
(Cerpa et al., 2011). These findings suggest that misregulation
of this pathway likely contributes to synaptic dysfunction
in neurodegenerative diseases, including Alzheimer’s disease
(AD) (Inestrosa et al., 2007).
AD is characterized by synaptic loss and progressive cognitive
deficits and is the most common cause of dementia affecting a
growing population of elderly individuals (Thies and Bleiler,
2013). The neuropathological hallmarks of AD are the presence
of amyloid-b (Ab) plaques and neurofibrillary tangles, along
with dystrophic neurites and gliosis (Holtzman et al., 2011). Ab,
generated from sequential proteolytic processing of b-amyloid
precursor protein (APP) through b- and g-secretases (Chami
and Checler, 2012; Cole and Vassar, 2007; Steiner and Haass,
2000), has been shown to disrupt synapses and initiate a
cascade of toxic events that lead to eventual neuronal loss
(Shankar et al., 2008). In addition to amyloid pathogenesis, syn-
aptic dysfunction is an early feature of AD, perhaps even prior to
Ab deposition (Arendt, 2009; Selkoe, 2002). Consistent with this
notion, disturbance in synaptic integrity is detected in patients
with mild cognitive impairment, a prodromal state of AD (Scheff
et al., 2006). Indeed, loss of synaptic markers is a strong predic-
tor of clinical symptoms and disease progression in AD (Selkoe,
2002). Thus, understanding molecular pathways underlying syn-
aptic dysfunction in AD will help to define specific molecular tar-
gets for therapy. Genome-wide association studies have defined
a broad susceptibility region for late-onset AD on chromosome
12, which includes the region encoding LRP6 (De Ferrari et al.,
2007). Indeed, two LRP6 SNPs and an alternative splice variant
were found to be associated with increased risk of developing
AD, which is most likely due to a suppression of Wnt signalingNeuron 84, 63–77, October 1, 2014 ª2014 Elsevier Inc. 63
Figure 1. Neuronal LRP6 Deficiency Leads to Synaptic Dysfunction, Memory Impairments, and Dendritic Spine Loss in Aged Mice
(A) LRP6 expression levels in the cortex of control (Ctrl) and Lrp6 cKO (cKO)mice (n = 3, per genotype) examined at 3, 6, 12, and 18months of age (n = 3, each age)
by real-time PCR. Results were normalized to b-actin levels. In the following figures, data are normalized to those of Ctrl mice for comparison. Values are mean ±
SEM. **p < 0.01.
(B andC) Total and free b-catenin (b-cat) levels in the cortex of Ctrl and Lrp6 cKOmice at indicated ages. Free b-catenin levels were evaluated byGST-E-cadherin
pull-down, followed by western blot analysis. Data represent mean ± SEM. *p < 0.05; **p < 0.01.
(legend continued on next page)
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these implications, the molecular mechanism by which LRP6
regulates AD pathogenesis is poorly understood. We thus fo-
cused on testing how an impairment of LRP6 function impacts
AD pathogenesis and examining potential changes in LRP6-
mediated Wnt signaling in human AD brains.
Herein, we show that deletion of neuronal Lrp6 in mice is suf-
ficient to cause age-dependent synaptic loss and memory im-
pairments. In addition, LRP6 deficiency in neurons exacerbates
amyloid pathology and cognitive deficits in an amyloid mouse
model. Furthermore, LRP6-mediated Wnt signaling is downre-
gulated in postmortem AD brains and negatively correlates
with Ab levels. Our findings define a critical role of LRP6-medi-
ated Wnt signaling in synaptic integrity and establish that an
impairment of this pathway contributes to AD pathogenesis.
RESULTS
Neuronal LRP6 Deficiency Leads to Cognitive
Impairment, Synaptic Deficits, and Neuroinflammation
in Aged Mice
Emerging studies have shown that Wnt signaling regulates syn-
aptic function and plasticity (Inestrosa and Varela-Nallar, 2013;
Jensen et al., 2012). To investigate the potential role of neuronal
LRP6, we conditionally deleted the Lrp6 gene in neurons by
crossing Lrp6flox/flox mice (Joeng et al., 2011; Zhong et al.,
2012) with calcium/calmodulin-dependent protein kinase II
alpha (CaMKII-Cre) mice (Tsien et al., 1996), generating Lrp6
conditional knockout (Lrp6 cKO) mice and their corresponding
littermate control (Ctrl) mice. As the Cre recombinase is ex-
pressed in postnatal forebrain (Tsien et al., 1996), LRP6 levels
in the cortex of Lrp6 cKO mice were significantly decreased at
3 months of age, which progressively reached maximal deletion
at 12 months of age (Figure 1A). The residual LRP6 observed at
older ages likely represents the expression within glial cells and/
or brain vasculature (Ren et al., 2013; Wang et al., 2004). Consis-
tent with a neuronal deletion of LRP6, free b-catenin levels were
significantly decreased in the cortex of Lrp6 cKO mice at
different ages (Figures 1B and 1C).
To examine the potential roles of neuronal LRP6 in cognition,
the memory function of Lrp6 cKO mice and their age-matched
controls was analyzed by contextual and cued fear conditioning
tests. In this behavioral paradigm, animals were exposed to an
auditory stimulus followed by a mild electric foot shock. Upon(D) The cognitive function of Ctrl (n = 15) and Lrp6 cKO (n = 18) mice at 22 mon
showing freezing behavior in response to stimulus during contextual or cued me
(E) Impaired hippocampal LTP in the CA1 region of Lrp6 cKO mice compared to
tetanus (at 100 Hz for 1 s, repeated three times) were summarized during recording
represent mean ± SEM. **p < 0.01. Representative traces before (1) and after (2
above fEPSP recording. Scale bars depict 10 ms and 0.1 mV.
(F) Averages of the last 5 min of fEPSP recording. Data represent mean ± SEM.
(G and I) Representative Golgi-impregnated neurons in hippocampal CA1 region
Scale bars, 10 mm.
(H and J) Representative apical oblique and basal shaft dendrites from hippocamp
of apical oblique (n = 100 dendritic segments on 50 neurons from fivemice of each
mice of each genotype) dendrites (70 mm segments) were counted. The spine den
**p < 0.01.
See also Figures S1 and S2.re-exposure to the same environment (contextual test) 24 hr
later, animals with intact cognition will freeze more. Likewise,
animals with intact cognition placed in an altered environment
will display freezing behavior upon hearing the auditory stimulus
(cued test). These two tasks test associative memory, which de-
pends on the function of hippocampus, or in case of cued test,
also amygdala. We found that LRP6 deficiency resulted in sig-
nificant memory deficits in Lrp6 cKO mice at 22 months of
age as assessed by contextual and cued fear conditioning tests
(Figure 1D). Interestingly, we did not observe significant differ-
ences in memory- and anxiety-related behaviors between Ctrl
and Lrp6 cKO mice at 6 months of age (Figures S1A–S1C avail-
able online), suggesting that memory impairments associated
with neuronal LRP6 deletion is age dependent. We also exam-
ined the effects of LRP6 deficiency on general behaviors
including those that measure locomotor activity and anxiety
levels by open field, light/dark exploration and elevated plus
maze paradigms. We found that the locomotor activity and anx-
iety behaviors were not affected in Lrp6 cKO mice at old ages
(Figures S1D–S1F), indicating that the observed cognitive
impairment in Lrp6 cKO mice was not due to anxiety. Further-
more, to investigate whether LRP6 regulates motor learning
and coordination, Ctrl and Lrp6 cKO mice were subjected to
the rotarod test, but no significant differences were detected
between genotypes (Figure S1G). These results indicate that
LRP6 deficiency in neurons selectively impairs memory perfor-
mance in aged animals.
The plasticity of synapses and dendritic spines is critical for
learning and memory. Given that Lrp6 cKO mice exhibited sig-
nificant cognitive deficits at old ages, we next investigated the
effect of neuronal LRP6 deficiency on long-term potentiation
(LTP), a neurophysiological measure that correlates with learning
and memory. The synaptic plasticity was evaluated after tetanic
stimulation and upon recording of field excitatory postsynaptic
potentials (fEPSPs) in Ctrl and Lrp6 cKO mice at 18 months of
age. Importantly, we found that LRP6 deficiency in neurons
leads to impaired LTP induction and maintenance (Figure 1E).
Hippocampal LTP in the Schaffer collaterals of Lrp6 cKO mice
decayed sharply within 25 min compared with Ctrl mice, sug-
gesting that Lrp6 cKO mice failed to maintain the potentiated
state (Figures 1E and 1F). LRP6 deletion did not lead to signifi-
cant changes in LTP in young mice (Figures S2A and S2B), sug-
gesting that this defect in synaptic plasticity of Lrp6 cKO mice is
age dependent.ths of age examined by fear conditioning tests. The percentage of time spent
mory tests is shown. Data represent mean ± SEM. **p < 0.01.
Ctrl mice. Normalized fEPSP responses to field stimulation before and after
fromCA1 region of Ctrl (n = 13) and Lrp6 cKO (n = 12) hippocampal slices. Data
) tetanic stimulation from the recordings of Ctrl and Lrp6 cKO mice are shown
**p < 0.01.
(G) and cortical layer II/III (I) from Ctrl and Lrp6 cKO mice at 18 months of age.
al CA1 region (H) and cortical layers II/III (J). Scale bars, 10 mm. Spine numbers
genotype) and basal shaft (n = 100 dendritic segments on 50 neurons from five
sities are expressed as mean spine number per 1 mm dendrite segment ± SEM.
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Figure 2. Compromised Synaptic Integrity and Enhanced Neuroinflammation in Neuronal LRP6-Deficient Mice
(A and B) The levels of synaptic markers in cortex and hippocampus (Hippo) of control (Ctrl) and Lrp6 cKO (cKO) mice at 6 months (n = 4 to 5 per genotype) and
18 months of age (n = 5–7 per genotype). Densitometric quantification is expressed as mean ± SEM. *p < 0.05; **p < 0.01; N.S., not significant.
(C) Representative images and quantification (n = 5–7 mice per genotype) of GFAP and Iba1 staining in the hippocampal CA1 region of Ctrl and Lrp6 cKOmice at
22months of age. Stained sections were scanned on the Aperio ScanScope slide scanner and analyzed using the ImageScope software. Scale bar, 100 mm.Data
represent mean ± SEM. *p < 0.05; **p < 0.01.
(D) The levels of GFAP in the hippocampus of Ctrl and Lrp6 cKOmice (n = 4 to 5 per genotype) examined by western blot. Data represent mean ± SEM. *p < 0.05.
(E) The levels of IL-1b and TNF-a in the hippocampus of Ctrl and Lrp6 cKO mice (n = 4) evaluated by ELISA. Data represent mean ± SEM. **p < 0.01.
See also Figure S2.
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excitatory synapses in the brain, and their morphological
changes are tightly correlated with synaptic strength (Yuste
and Bonhoeffer, 2001). As aged Lrp6 cKOmice exhibit abnormal
synaptic plasticity, we next examined the dendritic spine struc-
ture in Ctrl and Lrp6 cKO mice by Golgi staining. We observed
a significant dendritic spine loss in hippocampal CA1 and
cortical regions in Lrp6 cKOmice (Figures 1G and 1I). Moreover,
the spine density of both the pyramidal neurons from apical ob-
lique and basal shaft dendrites in the CA1 region of the hippo-
campus and layer II/III of the cortex were significantly decreased
in Lrp6 cKOmice at 18months of age (Figures 1H and 1J) but un-
altered at 6 months of age (Figures S2C–S2F). Together, these
results indicate that LRP6 plays critical roles in maintaining syn-
aptic functions and dendritic spine integrity in an age-dependent
manner.
We next analyzed the levels of synaptophysin and PSD-95,
presynaptic and postsynaptic markers, respectively, in the cor-
tex and hippocampus of Ctrl and Lrp6 cKO mice. There was
no significant difference in the levels of either synaptic marker66 Neuron 84, 63–77, October 1, 2014 ª2014 Elsevier Inc.between the two genotypes at 6 months of age (Figures 2A
and S2G). Importantly, we found a significant decrease in
PSD-95 levels in both the cortex and hippocampus of Lrp6
cKO mice compared with Ctrl mice at 18 months of age, while
the levels of synaptophysin were unchanged (Figure 2B). PSD-
95 is a core postsynaptic scaffold protein in mature excitatory
glutamatergic synapses, where two subtypes of glutamate
receptors (i.e., N-methyl-D-aspartate receptor [NMDAR] and
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid recep-
tor [AMPAR]) mediate synaptic transmission and plasticity. In
addition to PSD-95, the levels of NMDAR1 and AMPAR subunit
GluR1 were also reduced in the cortex of Lrp6 cKO mice
compared with Ctrl mice (Figure S2H). As a control, the levels
of synaptic markers were unaltered in the cerebellum, where
CaMKII-Cre is not active (Figure S2I). These results indicate
that LRP6 plays an important role in maintaining synaptic integ-
rity in aged mice.
The loss of synapses and dendritic spines in Lrp6 cKOmice led
us to hypothesize that LRP6 deficiency might lead to neuroin-
flammation. Using antibodies to glial fibrillary acidic protein
Figure 3. LRP6-Mediated Wnt Signaling Regulates Synaptic Integrity and Cell Survival in Primary Neurons
(A) LRP6 levels in control and LRP6-KD neurons examined by real-time PCR. **p < 0.01.
(B) Reduction in the levels of total and free b-catenin in LRP6-KD neurons compared with control neurons. Free b-catenin levels were evaluated by GST-E-
cadherin pull-down, followed by western blot analysis. Densitometric data are expressed as mean ± SEM. **p < 0.01.
(C) Western blot analyses of synaptic proteins (PSD-95, synaptophysin [Syp], NMDAR1, and GluR1) in control and LRP6-KD neurons. Densitometric data are
expressed as mean ± SEM. **p < 0.01; N.S., not significant.
(D) Representative confocal immunofluorescence images of presynaptic (synaptophysin, red) and postsynaptic protein clusters (PSD-95, green) in control and
LRP6-KD primary neurons. The specific dendritic marker, microtubule-associated protein (MAP2), is shown in magenta. Scale bar, 5 mm.
(E and F) The levels of PSD-95, total, and free b-catenin in LRP6-KD primary neurons treated with control vector or CA b-catenin (deletion of amino acids 1–90)
examined by western blot. Densitometric analysis of PSD-95 level is shown as mean ± SEM. **p < 0.01.
(G and H) Cell morphology and viability in control or LRP6-KD primary neurons (4 d knockdown) examined by MAP2 staining (G) and MTT assay (H). Scale bars,
50 mm (top panel) and 10 mm (bottom panel). MTT quantification data represent mean ± SEM. **p < 0.01.
(I) Levels of caspase-3 (Casp-3) and cleaved caspase-3 in control or LRP6-KD neurons assessed by western blot. Data represent mean ± SEM. **p < 0.01.
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which are markers for activation of astrocytes and microglia,
respectively, we found that GFAP-positive astrocytes and Iba1-
positive microglia in the hippocampus were significantly
increased in aged Lrp6 cKO mice (Figure 2C). The increase of
GFAP in Lrp6 cKOmice was also confirmed by western blot (Fig-
ure 2D). To further confirmmicroglial activation, wemeasured the
expression levels of proinflammatory cytokines interleukin-1b (IL-
1b) and tumor necrosis factor-a (TNF-a) by ELISA and found that
they were significantly increased in the hippocampus of aged
Lrp6 cKO mice (Figure 2E). These results indicate that loss of
neuronal LRP6 leads to neuroinflammation, which might further
damage synapses and contribute to cognitive dysfunction.LRP6-Mediated Wnt Signaling Is Critical for Synaptic
Integrity and Neuronal Viability
To further investigate whether LRP6 is required for maintaining
synaptic integrity, we established experimental conditions under
which LRP6was efficiently knocked down in primary neurons us-
ing lentivirus carrying LRP6 shRNA. As expected, upon LRP6
knockdown in mouse primary neurons (Figure 3A), the levels of
both total and free b-catenin were significantly decreased (Fig-
ure 3B), indicating a suppression of Wnt signaling. Consistent
with the effects of LRP6 deficiency in vivo, we observed a signif-
icant reduction in the levels of PSD-95, but not synaptophysin, in
LRP6-knockdown (LRP6-KD) neurons (Figure 3C). Furthermore,
LRP6 knockdown significantly suppressed the levels of NMDAR1Neuron 84, 63–77, October 1, 2014 ª2014 Elsevier Inc. 67
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Impaired Wnt Signaling Promotes AD Pathogenesisand GluR1 (Figure 3C). Effects of LRP6 knockdown on synapses
were further confirmed by immunofluorescence staining. We
found that PSD-95-positive, but not synaptophysin-positive,
puncta were significantly reduced in LRP6-KD neurons (Fig-
ure 3D). These results suggest that LRP6-mediatedWnt signaling
plays an important role in maintaining postsynaptic integrity.
To examine whether effects of LRP6 knockdown on synaptic
integrity can be rescued by restoring downstreamWnt signaling,
LRP6-KD neurons were infected with lentivirus expressing a
constitutively active form of b-catenin (CA b-catenin) (Guo
et al., 2012). We found that forced expression of CA b-catenin
significantly enhanced Wnt signaling activation and partially
rescued the level of PSD-95 (Figures 3E and 3F). This result
further suggests that LRP6 and LRP6-dependent Wnt signaling
are important for synaptic integrity, particularly at the postsyn-
aptic sites.
Next, to determine whether downregulation of LRP6 induces
neuronal death, we evaluated changes in neuronal morphology
and cell viability following LRP6 shRNA infection. Prolonged
LRP6 knockdown induced pronounced neuritic dystrophy and
neuronal loss compared with control treatments (Figures 3G
and 3H). Furthermore, LRP6 downregulation resulted in activation
of caspase-3 in LRP6-KD neurons (Figure 3I), indicating that the
decreased cell survival was due to an induction of apoptosis.
These results support a role of LRP6-mediated Wnt signaling in
regulating postsynaptic integrity and neuronal survival.
Neuronal LRP6 Deficiency Increases Ab Levels
and Exacerbates Amyloid Pathology in an Amyloid
Mouse Model
To examine whether LRP6 modulates amyloid pathology, we
next examined endogenous Ab levels in the brain of Lrp6 cKO
mice. We found that neuronal LRP6 deficiency significantly
increased mouse endogenous Ab40 and Ab42 levels in the brain
compared with Ctrl mice (Figure 4A). To assess the roles of LRP6
in APP processing, we investigated the effects of LRP6 deletion
on various APP processing products, including soluble APP ec-
todomains (sAPPa and sAPPb) and C-terminal fragments (CTFa
and CTFb). The levels of sAPPb andCTFbwere slightly yet signif-
icantly increased in the cortex of Lrp6 cKOmice, while total APP
remains unchanged (Figure 4B).
To further examine whether LRP6 deficiency in neurons influ-
ences amyloid pathology, we bred Lrp6 cKO mice into the
background of APPswe/PS1DE9 (APP/PS1) amyloid mouse
model, which exhibit accelerated Ab amyloidosis (Jankowsky
et al., 2004). When the plaque burdens in APP/PS1; Lrp6 cKO
(APP/PS1; cKO) mice and littermate control (APP/PS1; Ctrl)
mice were compared by immunohistochemical staining, amy-
loid plaque loads in the cortex and hippocampus were markedly
higher in APP/PS1; Lrp6 cKO mice compared with APP/PS1;
Ctrl mice at 9 months of age (Figure 4C). We also found corre-
sponding increases in the levels of insoluble Ab40 and Ab42 in
APP/PS1; Lrp6 cKO mice (Figures 4D and 4E). When amyloid
plaque loads were assessed in mice at 6 months of age, APP/
PS1; Lrp6 cKO mice also had more Ab deposition in the cortex
than APP/PS1; Ctrl mice (Figures S3A and S3B). These results
indicate that loss of neuronal LRP6 leads to increased amyloid
pathology.68 Neuron 84, 63–77, October 1, 2014 ª2014 Elsevier Inc.We next compared the extent of neuroinflammation in APP/
PS1; Lrp6 cKO and APP/PS1; Ctrl mice by immunohistochem-
ical staining using GFAP and Iba1 antibodies and observed a
profound increase in astrocyte and microglia activation in APP/
PS1; Lrp6 cKO mice (Figures 4F and S3C). To examine whether
these pathological events correlate with cognitive deficits, we
next evaluated the memory performance of APP/PS1; Lrp6
cKO and their littermate APP/PS1; Ctrl mice at 12 months of
age by fear conditioning tests. We found that APP/PS1; Lrp6
cKO mice exhibited significant deficits in both contextual and
cued fear conditioning compared to APP/PS1; Ctrl mice (Fig-
ure 4G). To minimize potentially confounding factors, such as
anxiety, we also examined general behaviors including locomo-
tor activity and anxiety levels by open field and light/dark explo-
ration paradigms. No significant deficits were observed in these
non-memory-related tests in APP/PS1; Lrp6 cKO mice (Figures
S3D and S3E). Together, these results indicate that impairment
of LRP6-mediated Wnt signaling directly leads to increased am-
yloid pathology and cognitive deficits.
LRP6 Regulates APP Trafficking and Processing to Ab
To investigate the potential mechanism by which LRP6 regulates
Ab levels, we knocked down LRP6 expression in human neu-
roblastoma SH-SY5Y cells overexpressing human APP (SH-
SY5Y-APP) (Kounnas et al., 2010) with lentivirus carrying LRP6
shRNA (Figure 5A). Consistent with our in vivo findings, LRP6
knockdown significantly increased the levels of both Ab40 and
Ab42 (Figure 5B). Similar effects were observed in mouse neuro-
blastoma N2a cells overexpressing human APP (N2a-APP)
treated with LRP6 shRNA (Figures S4A–S4D). Although LRP5
and LRP6 are homologous, the expression of LRP5 in neurons
and brain is very low compared to LRP6 (Figure S5A) (Dong
et al., 1998). As an alternative control, we tested the effect of
knocking down the expression of low-density lipoprotein recep-
tor (LDLR), another member of the LDLR family that is abundantly
expressed in the brain but does not bind to APP in N2a-APP cells
on Ab production. As expected, we did not detect any significant
effects of knocking down LDLR on Ab production (Figures S5B
and S5C), suggesting that the observed effects of LRP6 knock-
down on Ab is specific. Conversely, overexpression of LRP6
together with Mesd, a specialized chaperone for the proper
folding of LRP6, resulted in a significant decrease of both Ab40
and Ab42 levels (Figures 5C and 5D). While exogenously admin-
istration of Mesd is known to moderately suppress Wnt signaling
(Liu et al., 2010a), Mesd cotransfection with LRP6 as an ER chap-
eronedidnot result inMesd secretion to themedium (FigureS5D);
thus, it should not affect LRP6-mediated Wnt signaling. As a
negative control for overexpression, cotransfection of LDLR
andAPP inHEK293 cells did not lead to changes in Ab production
(Figure S5E). Together, these results indicate that LRP6 sup-
presses Ab production.
To examine whether there is specific interaction between
LRP6 and APP, we performed coimmunoprecipitation assays
in HEK293 cells cotransfected with APP and LRP6/Mesd. We
found that APP was significantly coimmunoprecipitated with
LRP6; correspondingly, immunoprecipitation of APP pulled
down LRP6 (Figure 5E). To further identify the interacting do-
mains in LRP6 and APP, HEK293 cells were transfected with
Figure 4. LRP6 Deficiency in Neurons Exacerbates Amyloid Pathology, Cognitive Impairment, and Neuroinflammation
(A) The endogenous Ab levels in the cortex of 12-month-old control (Ctrl) and Lrp6 cKO (cKO) mice (n = 5/ per group). *p < 0.05; **p < 0.01.
(B) Levels of full-length APP and various APP processing fragments evaluated in Ctrl and Lrp6 cKO mice (n = 5/ per group) by western blot analysis and
densitometric analyses. *p < 0.05; N.S., not significant.
(C) Brain sections from APP/PS1; Ctrl and APP/PS1; cKOmice (n = 5 per group) at 9 months of age immunostained for Ab. Scale bar, 100 mm. The percentage of
area covered by plaques was quantified, and the plaque load was normalized to that of APP/PS1; Ctrl mice. Values are mean ± SEM. *p < 0.05.
(D and E) Ab40 and Ab42 levels in the GDN fraction of APP/PS1; Ctrl and APP/PS1; cKO mice (n = 5 per group) at 9 months of age. Values are mean ± SEM. *p <
0.05; **p < 0.01.
(F) Cortical sections from APP/PS1; Ctrl and APP/PS1; cKO mice at 9 months of age immunostained with GFAP antibody. Scale bar, 50 mm. The percentage of
area covered by GFAP staining was quantified (n = 5 per group). Values are mean ± SEM. *p < 0.05.
(G) The cognitive function of APP/PS1; Ctrl and APP/PS1; cKOmice (n = 14 per group) at 12months of age examined by fear conditioning tests. The percentage of
time spent showing freezing behavior in response to stimulus during contextual or cued memory tests is shown. Data represent mean ± SEM. **p < 0.01.
See also Figure S3.
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deletions (Figures S5F and S5G). All APP-truncated proteins
were expressed at the expected sizes as determined by western
blotting (Figure S5H). We then immunoprecipitated APP (anti-
myc) and probed for LRP6 (anti-HA) and found that LRP6 was
coimmunoprecipitated with full-length APP, APP-E2 and APP-
DE1 (Figure S5I), but not with APP-E1, APP-DE1E2, and C99(Figure S5J). These results indicate that APP-E2 domain is
necessary and sufficient for APP-LRP6 interaction. To determine
the LRP6 domain required for the APP-LRP6 interaction, we co-
transfected cells with APP together with LRP6 constructs with
either cytoplasmic domain deletion (LRP6DC) or extracellular
deletion (LRP6DN) (Figure S5G). The LRP6 truncated plasmids
were expressed at the expected sizes (Figure S5K), and weNeuron 84, 63–77, October 1, 2014 ª2014 Elsevier Inc. 69
Figure 5. LRP6 Regulates APP Trafficking and Processing to Ab
(A) The levels of LRP6, APP, and b-actin in SH-SY5Y-APP cells expressing control and LRP6 shRNA examined by western blot analysis.
(B) The levels of Ab40 or Ab42 in the media of SH-SY5Y-APP cells expressing control and LRP6 shRNA evaluated by ELISA. Values are mean ± SD. *p < 0.05.
(C) The levels of LRP6, APP, and b-actin in HEK293 cells overexpressing APP with either vector or LRP6/Mesd analyzed by western blot.
(D) The levels of Ab40 or Ab42 in the media of HEK293 cells overexpressing APP with either vector or LRP6/Mesd analyzed by ELISA. Data represent mean ± SD;
*p < 0.05; **p < 0.01.
(E) Coimmunoprecipitation of LRP6 and APP in HEK293 cells cotransfectedwithmyc-APP (wild-type or Swedishmutant) and HA-LRP6/Mesd. Normalmouse IgG
was used as a negative control. IP, immunoprecipitation.
(F and G) The levels of APP, APP-CTFs, soluble APP fragments, and b-actin in N2a-APP cells expressing control and LRP6 shRNA examined by western blot.
Data represent mean ± SD; **p < 0.01; N.S., not significant.
(legend continued on next page)
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with APP (Figure S5L), suggesting that LRP6 extracellular region
is required for this interaction.
To examine whether LRP6 regulates APP processing, we
knocked down LRP6 expression in N2a-APP cells and analyzed
potential effects on the levels of APP and its processing prod-
ucts. We found that LRP6 knockdown significantly increased
the levels of sAPPb and CTFb without affecting full-length APP
(Figures 5F and 5G). Current models of Ab generation suggest
that APP is cleaved by b-secretases in early endosomes (Vetrivel
and Thinakaran, 2006), whereas retention of APP at the cell sur-
face increases sAPPa levels and decreases Ab production
(Carey et al., 2005; Haass et al., 1993). Interestingly, we found
that cell surface APP was significantly decreased in LRP6-KD
cells (Figure 5H). In addition, overexpression of LRP6 with
Mesd significantly increased Wnt signaling and the levels of
sAPPa without affecting the level of full-length APP (Figures 5I
and S4E–S4G). To examine whether increased sAPPa is due to
increased cell surface APP, primary neurons were cotransfected
with GFP-APP together with either control vector or LRP6/Mesd,
and the level of cell surface APP was quantified as previously
described (Hoe et al., 2009; Megill et al., 2013). We found that
overexpression of LRP6 significantly enhanced cell surface
APP level (Figure 5J). The increased cell surface APP upon
LRP6 overexpression was also confirmed by cell surface bio-
tinylation assay (Figure 5K). These results suggest that LRP6
interaction with APP leads to increased cell surface APP, which
favors non-amyloidogenic processing by a-secretase and a
concomitant reduction of Ab production.
LRP6 Levels and Wnt Signaling Are Downregulated
in AD Brains
To address the relevance of LRP6-mediated Wnt signaling
pathway in human AD, we analyzed LRP6 levels in the temporal
cortex from postmortem brains of AD patients (n = 18, average
age 84.2 ± 4.1 years old) and age-matched controls (n = 20,
average age 85.1 ± 5.7 years old) (Table S1). LRP6 mRNA and
protein levels were significantly lower in AD cases compared to
age-matched controls, as assessed by quantitative RT-PCR
and western blotting (Figures 6A, 6B, and S6A). As comparison,
the levels of LRP5 (Figure S6B) and a membrane protein Na+/K+
ATPase (Figures S6D and S6E) were not changed in AD brains
compared to those of controls. In addition, there was no signifi-
cant difference in the levels of neuronal b-tubulin and synapto-
physin, although, as expected, PSD-95 level was decreased in
AD patients compared with control individuals (Figures S6D
and S6E). As LRP6 is an essential Wnt signaling receptor, we
found that the levels of both total b-catenin and free b-catenin,(H) The levels of total and cell surface LRP6 in SH-SY5Y-APP or N2a-APP cells e
SD; *p < 0.05.
(I) The levels of sAPPa and full-length APP in HEK293 cells overexpressing APP
mean ± SD; **p < 0.01.
(J) Primary neurons transfected with GFP-APP together with vector or LRP6/Mesd
and quantified (n = 8–10). Data represent mean ± SD; **p < 0.01.
(K) The levels of cell surface and total APP in COS7 cells overexpressing APP tog
Data represent mean ± SD; **p < 0.01.
See also Figures S4 and S5.which translocates to the nucleus to activate Wnt signaling
(Nelson and Nusse, 2004), were lower among AD cases than
controls (Figures 6C, 6D, and S6F). Interestingly, the levels of
LRP6 positively correlated with those of free b-catenin (r =
0.75, p < 0.001) and to a lesser extent with that of total b-catenin
(r = 0.38, p = 0.03) (Figures 6E and 6F). These results indicate that
the decreased levels of LRP6 likely contribute to compromised
Wnt signaling in AD brains.
To analyze the relationship between LRP6 level and the dy-
namic pools of Ab, we fractionated human brain samples into
TBS-soluble, detergent-soluble (TBSX), and insoluble (guani-
dine-HCl, GDN) fractions (Youmans et al., 2011) and quantified
Ab levels by ELISA. As expected, Ab42 (Figure 6G) and Ab40
(Figure S6G) levels were significantly higher in the brains of AD
cases compared with controls in all fractions. We also found
that LRP6 at both mRNA level (Figure 6H) and protein level (Fig-
ure S6H) inversely correlate with those of Ab42 in the TBS, TBSX,
and GDN fractions, suggesting that accumulation of Abmight be
associated with downregulation of LRP6 expression. Similar
negative correlations were observed between LRP6 and Ab40
in all fractions (Figures S6I and S6J). Furthermore, LRP6 at the
protein level was positively correlated with mini-mental state ex-
amination score (r = 0.57, p = 0.001) (Figure S6C), a widely used
tool for assessing cognitive function (Folstein et al., 1975). We
also observed slight decrease in free b-catenin and LRP6 levels
in aged APP/PS1 mice (Figures S7A and S7B), consistent with a
previous finding (Toledo and Inestrosa, 2010). Together, these
results imply that suppression of LRP6-mediated Wnt signaling
likely contribute to AD pathogenesis.
Ab Downregulates LRP6-Mediated Wnt Signaling
Our data indicated that LRP6-mediated Wnt signaling is
compromised in AD brain tissues compared to controls (Figures
6C and 6D). To investigate the potential mechanism underlying
this observation, we examined the levels of Wnt signaling in
N2a-pcDNA control and N2a-APP cells. While total b-catenin
and free b-catenin levels were significantly downregulated in
N2a-APP cells compared to control cells, this suppression was
partially restored upon administration of a b-secretase or g-sec-
retase inhibitor (Figures 7A–7D). Since treatments of these inhib-
itors significantly suppressed Ab production and altered the
levels of APP fragments (Figures S7C–S7F), these results sug-
gest that APP processing mediated by these secretases is
required for this event. To examine if the observed effect is medi-
ated by Ab, we treated primary neurons with Ab42 oligomers
and found that the levels of free b-catenin were downregulated
(Figure 7E). We also found that Ab42 oligomers downregulated
LRP6 levels and suppressed Wnt signaling in SH-SY5Y cellsxpressing control and LRP6 shRNA analyzed by FACS. Data represent mean ±
with either vector or LRP6/Mesd examined by western blot. Data represent
for 24 hr. Cell surface APPwas examined by immunofluorescencemicroscopy
ether with vector or LRP6/Mesd examined by cell surface biotinylation assay.
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Figure 6. Decreased LRP6 and Wnt Signaling in Human AD Brains
(A) LRP6mRNA levels in human control (n = 20) and AD (n = 18) brain tissues quantified by real-time PCR. Results are normalized to b-actin levels and presented in
relative units. In the following figures, data are shown as scatterplots in which each symbol represents an individual case. A.U., arbitrary unit. Data represent
mean ± SEM. **p < 0.01.
(B) LRP6 protein levels in human control (n = 17) and AD (n = 17) brain tissues quantified by western blot analysis. Data represent mean ± SEM. **p < 0.01.
(C and D) The total and free b-catenin levels in human control (n = 16) and AD (n = 16) brain tissues examined by western blot analysis. Free b-catenin levels were
analyzed by GST-E-cadherin pull-down assay. Data represent mean ± SEM. **p < 0.01.
(E) Correlation between LRP6 protein levels and free b-catenin levels in human control (dark circles) and AD (light circles) brain tissues (r represents the correlation
coefficient; p is significance).
(F) Correlation between LRP6 protein levels and total b-catenin levels in human control (dark circles) and AD (light circles) brain tissues.
(G) Ab42 levels in TBS, TBSX, and GDN fractions of human control (n = 20) and AD (n = 18) brain tissues. Data represent mean ± SEM. **p < 0.01.
(H) Correlation between LRP6 mRNA levels in (A) and those of Ab42 in various extraction fractions (TBS, TBSX, or GDN) in (G) in human control (dark circles) and
AD (light circles) brain tissues.
See also Figure S6 and Table S1.
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gands mitigated the Ab-induced suppression of Wnt signaling
(Figure S7G), suggesting that upregulation of Wnt signaling
might ameliorate Ab toxicity. Together, our results suggest that
Ab likely downregulates LRP6 expression and its associated
Wnt signaling, thus initiating a vicious cycle in which decreased
LRP6 and increased Ab levels in AD brains synergistically pro-
mote AD pathogenesis.
DISCUSSION
Mounting evidence demonstrates that synaptic dysfunction and
substantial amyloid buildup are present in AD brains long before
the clinical onset of the disease (Huang and Mucke, 2012; Tar-
awneh and Holtzman, 2010). Identifying the molecular mecha-72 Neuron 84, 63–77, October 1, 2014 ª2014 Elsevier Inc.nisms that contribute to these pathogenic processes may help
to develop new therapeutic approaches for the prevention and
treatment of AD. Toward this effort, we sought to define critical
pathways regulating AD pathogenesis. Genetic evidence has
suggested a role of LRP6-mediated Wnt signaling in AD patho-
genesis; however, biological and pathological evidences are
lacking. In this report, using in vivo animal and in vitro cellular
models, we demonstrated a critical role for LRP6 and its asso-
ciated Wnt signaling in maintaining synaptic integrity and func-
tions. We also found that LRP6 deficiency in neurons leads
to increased Ab accumulation and amyloid pathology by accel-
erating APP processing to Ab, which in turn downregulates
LRP6-mediated Wnt signaling. Although we cannot rule out the
possibility that APP intracellular domain or soluble APP frag-
ments also have inhibitory effects on Wnt signaling (Zhou et al.,
Figure 7. Ab Suppresses LRP6 Expression and Wnt Signaling Activation
(A–D) The levels of total b-catenin, free b-catenin, APP, and b-actin in N2a-pcDNA and N2a-APP cells in the presence or absence of a BACE inhibitor (b-secretase
inhibitor IV, 2 mM) or a g-secretase inhibitor (DAPT, 10 mM) examined by western blot. Free b-catenin levels were analyzed by GST-E-cadherin pull-down assay.
Data represent mean ± SEM. *p < 0.05; **p < 0.01. N.S., not significant.
(E) The levels of total and free b-catenin in primary neurons treated with 5 mM Ab42 oligomers examined by western blot. Data represent mean ± SEM. *p < 0.05;
N.S., not significant.
(F) Illustrative diagram depicting a potential vicious cycle between increased Ab and decreased LRP6-mediated Wnt signaling in AD pathogenesis. See text for
details.
See also Figure S7.
Neuron
Impaired Wnt Signaling Promotes AD Pathogenesis2012), our evidence points to a direct effect of Ab oligomer on
downregulating LRP6-mediated Wnt signaling. We further
showed that LRP6-mediated Wnt signaling is compromised in
AD brains. Thus, downregulated LRP6/Wnt signaling and
increased Ab pathology in AD brains constitute a vicious cycle
in which the two events synergistically promote synaptic
dysfunction, leading to eventual neurodegeneration in AD (Fig-
ure 7F). Although LRP5 is a homologous receptor of LRP6, these
two receptors likely mediate distinct actions through the differ-
ences in tissue distribution and affinity for individual Wnt ligands
(Mi and Johnson, 2005). Global deletion of the Lrp6 gene in mice
results in significant brain abnormalities, while deletion of the
Lrp5 gene leads to abnormality primarily in bone density (Cas-
telo-Branco et al., 2010; Gong et al., 2001). A previous study
has also shown that LRP5 is expressed at a very low level inthe nervous system (Dong et al., 1998), consistent with our cur-
rent findings. Thus, LRP6, rather than LRP5, is likely the primary
canonical Wnt signaling receptor in the brain under both physio-
logical and pathological conditions.
Wnt signaling plays a critical role in spine morphogenesis and
neurotransmission during development and in mature neurons
(Inestrosa and Arenas, 2010). During development, several Friz-
zled Wnt receptors are known to be involved in synaptogenesis
and synaptic connectivity (Sahores et al., 2010). Moreover,
different ligands have been found to regulate synaptic structure
and function in both presynaptic and postsynaptic regions (Ines-
trosa and Varela-Nallar, 2013). In addition, the release of Wnt
ligands and the activated signaling cascade are modulated by
neuronal activity, suggesting the importance of this pathway in
synaptic plasticity (Ataman et al., 2008). In the adult brain, ourNeuron 84, 63–77, October 1, 2014 ª2014 Elsevier Inc. 73
Neuron
Impaired Wnt Signaling Promotes AD Pathogenesiscurrent results show that neuronal LRP6 regulates synaptic
plasticity, likely through the modulation of components at post-
synaptic sites. However, we cannot exclude the possibility that
Wnt-independent functions might also play a role in LRP6-regu-
lated pathways in synapses. LRP6 is required for efficient activa-
tion of Gas-mediated cyclic adenosine monophosphate (cAMP)
signaling by various guanine nucleotide-binding protein (G pro-
tein)-coupled receptors (Wan et al., 2011). It is possible that loss
of LRP6 in neurons attenuates cAMP-response-element-binding
protein (CREB) signaling essential for synaptic plasticity, resulting
in synaptic abnormalities and cognitive decline (Bourtchuladze
et al., 1994). In our studies, Lrp6 cKOmice displaymarked hippo-
campal LTP impairment in the Schaffer collateral CA1 synapses.
These results suggest that LRP6might mediate the proper main-
tenance of glutamate receptors in dendritic spines where CA1
LTP is an NMDA-dependent postsynaptic phenomenon control-
ling AMPA receptor function (Dea´k and Sonntag, 2012). Thus,
determining whether LRP6 alters the trafficking and stability of
glutamate receptors and whether such events are dependent
upon Wnt signaling warrants further investigation.
A common variant of LRP6 (Ile-1062/Val), which suppresses
Wnt signaling, has been shown to be a genetic risk factor for late-
onset AD (De Ferrari et al., 2007). LRP6 genetic variants have
also been linked to other disorders frequently seen in the elderly
(Ding et al., 2011); single-nucleotide polymorphisms of the LRP6
gene significantly increases the risk of osteoporosis (van Meurs
et al., 2006) and macular degeneration (Haines et al., 2006). In
addition, LRP6 regulates glucose and lipid metabolism; a rare
loss-of-function mutation in LRP6 (Arg-611/Cys) is linked to
early-onset coronary artery disease, metabolic syndrome, and
insulin resistance (Mani et al., 2007; Singh et al., 2013), condi-
tions that are known to increase the risk for AD (Razay et al.,
2007; Sims-Robinson et al., 2010). Therefore, it is possible that
suppression of LRP6-mediatedWnt signaling increases the risks
of dyslipidemia and insulin resistance, which might further exac-
erbate AD pathogenesis (Sims-Robinson et al., 2010). Impor-
tantly, we demonstrated that LRP6 levels and Wnt signaling
are significantly reduced in postmortem brains from late-onset
AD patients. Consistent with our findings, altered expression of
several Wnt signaling components has been implicated in the
pathogenesis of AD (Caricasole et al., 2004; He and Shen,
2009; Wan et al., 2014). In addition, the levels of b-catenin are
significantly reduced in AD individuals bearing presenilin-1 mu-
tations (Nishimura et al., 1999). Conversely, Dickkopf-1, a well-
known antagonist of the Wnt pathway, is increased in AD brains,
upregulated by Ab treatment, and associated with Ab-mediated
synaptic loss (Caricasole et al., 2004; Purro et al., 2012).
Glycogen synthase kinase 3 (GSK3), which is negatively regu-
lated by LRP6-mediated Wnt signaling, plays a central role in
AD and its misregulation accounts for several pathological hall-
marks of the disease, including hyperphosphorylation of tau
and amyloid plaque formation (Hooper et al., 2008). Such evi-
dence, in combination with our findings, indicates that LRP6
perturbation is critically involved in AD pathogenesis and dem-
onstrates the need for future studies aimed at uncovering the
mechanisms through which LRP6 is downregulated in AD.
Our results also suggest that deficiency in LRP6-mediated
Wnt signaling might exacerbate neuronal vulnerability to Ab74 Neuron 84, 63–77, October 1, 2014 ª2014 Elsevier Inc.toxicity in AD brains, in addition to their direct effects on synap-
ses. Emerging evidence supports a neuroprotective role for
Wnt signaling in neurodegenerative disorders, including AD (In-
estrosa and Toledo, 2008). Activation of Wnt signaling protects
hippocampal neurons from Ab toxicity (Alvarez et al., 2004).
Treatment with lithium, which activates Wnt signaling by inhibi-
tion of GSK3b, was shown to reduce amyloid burden and amelio-
rate neurodegeneration in AD mouse models (Noble et al., 2005;
Rockenstein et al., 2007), though its use is limited by several
adverse effects (Pachet and Wisniewski, 2003). Our results
further indicate that LRP6-mediated Wnt signaling plays critical
roles in regulating both synaptic functions and amyloid pathol-
ogy and suggest that deficiency of this pathway contributes to
AD pathogenesis.
In summary, we have demonstrated that neuronal LRP6-medi-
ated Wnt signaling is critical for synaptic maintenance, cognitive
function, and amyloidogenesis. Our work identifies a signaling
pathway that contributes to AD pathogenesis and suggests
that restoring LRP6-mediated Wnt signaling in AD may be a
promising therapeutic strategy.
EXPERIMENTAL PROCEDURES
Human Postmortem Brain Tissues
Temporal lobe cortex samples from neurologically unimpaired subjects (n =
20) and from subjects with AD (n = 18) were obtained from the University of
Kentucky Alzheimer’s Disease Center (Lexington). Diagnosis of AD was
confirmed by pathological and clinical criteria. The average age of subjects
was 84.2 ± 4.1 years in the AD group and 85.1 ± 5.7 years in the control group
(p = 0.61). Average postmortem interval was 3.2 hr and was not significantly
different between the two groups (p = 0.28).
Animals
All animal procedures were approved by the Mayo Clinic Institutional Animal
Care and Use Committee (IACUC) and were in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals.
Lrp6flox/flox mice were a generous gift from Dr. Bart Williams (Van Andel
Research Institute, Grand Rapids). Double transgenic APPswe/PS1DE9
(APP/PS1) mice were purchased from Jackson Laboratory. See Supplemental
Experimental Procedures for details.
Golgi Staining and Dendritic Spine Analysis
Golgi staining was performed using the FD Rapid Golgi Stain kit (FD Neuro
Technologies) as described in Liu et al. (2010b). See Supplemental Experi-
mental Procedures for details.
Extracellular Field Recording from Acute Hippocampal Slices
Extracellular recordings were performed from acute hippocampal slices with
an adopted protocol as originally described in Oka et al. (1999). See Supple-
mental Experimental Procedures for details.
Behavioral Analysis
Learning and memory performance was assessed using a fear conditioning
paradigm. Freezing behavior was measured with an overhead camera and
FreezeFrame software (Actimetrics). Open field, elevated plus maze, and
light/dark exploration tests were used for the assessment of anxiety behaviors,
which were tracked with an overhead camera and AnyMaze software. The ro-
tarod test was used to examine the motor coordination and motor learning in
mice. See Supplemental Experimental Procedures for details.
Statistical Analysis
Comparisons between two groups were performed with Student’s t tests, and
those among more than two groups were performed with ANOVA. A p value
Neuron
Impaired Wnt Signaling Promotes AD Pathogenesisof < 0.05 was considered statistically significant. Correlations were analyzed
by Pearson correlation and regression tests.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2014.08.048.
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